Log In
Print
BCIQ
Print
Print this Print this
 

Sym006

  Manage Alerts
Collapse Summary General Information
Company Symphogen A/S
DescriptionRecombinant polyclonal antibody against Pseudomonas aeruginosa infections
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationPseudomonas
Indication DetailsTreat pseudomonas infection
Regulatory Designation

Partner

Meiji Seika Pharma Co. Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today